Synergism of FAK and ROS1 inhibitors in the treatment of CDH1-deficient cancers mediated by FAK-YAP signaling
Simultaneous inhibition of FAK and ROS1 synergistically repressed triple-negative breast cancer by upregulating p53 signalling
A phase Ib study of IN10018 in combination with pegylated liposomal doxorubicin (PLD) in patients with platinum-resistant ovarian cancer.
Focal adhesion kinase inhibitors, a heavy punch to cancer.
Time of issue 2021-11-25
Inhibition of focal adhesion kinase enhances antitumor response of radiation therapy in pancreatic cancer through CD8+ T cells.
Focal Adhesion Kinase (FAK) Inhibition Synergizes with KRAS G12C Inhibitors in Treating Cancer through the Regulation of the FAK-YAP Signaling.
Previous page
1
Next page
We invent personalized medicines with global impact, and turn innovation in China to life saving therapies for the world
QUICK LINKS
CONTACT US
Tel: +86 25-58251030
Email: office@inxmed.com
Office address: 73 Tanmi Road Block D-2, 3rd Floor Jiangbei New District, Nanjing
MESSAGE
Follow Us：
CopyRight © 2022 InxMed All Rights Reserved.